tiprankstipranks
Regen Biopharma (RGBP)
OTHER OTC:RGBP
US Market

Regen Biopharma (RGBP) Price & Analysis

122 Followers

RGBP Stock Chart & Stats

$0.01
>-$0.01(-11.86%)
At close: 4:00 PM EST
$0.01
>-$0.01(-11.86%)

RGBP FAQ

What was Regen Biopharma’s price range in the past 12 months?
Regen Biopharma lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
    What is Regen Biopharma’s market cap?
    Regen Biopharma’s market cap is $69.11K.
      When is Regen Biopharma’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Regen Biopharma’s earnings last quarter?
      Currently, no data Available
      Is Regen Biopharma overvalued?
      According to Wall Street analysts Regen Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Regen Biopharma pay dividends?
        Regen Biopharma does not currently pay dividends.
        What is Regen Biopharma’s EPS estimate?
        Regen Biopharma’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Regen Biopharma have?
        Regen Biopharma has 511,957,640 shares outstanding.
          What happened to Regen Biopharma’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Regen Biopharma?
          Currently, no hedge funds are holding shares in RGBP
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Regen Biopharma

            Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene. This modulation is strategically aimed at activating immune cells for oncology treatments and suppressing them for autoimmune conditions. Its therapeutic pipeline and product development are currently in their initial phases. Established in 2012, the firm operates from its headquarters in La Mesa, California.
            Similar Stocks
            Company
            Price & Change
            Follow
            Enveric Biosciences
            Aditxt
            Protagenic Therapeutics
            PMGC Holdings
            Popular Stocks